Technology | March 06, 2015

Re-engineered device introduces touchscreen technology, saline advance for CT angiograph

March 6, 2015 — Bracco Imaging, through its business unit Bracco Injeneering SA, announced the availability of its EmpowerCTA+, an advanced engineering contrast injection system.

The EmpowerCTA+ has initially been launched in the United States then gradually in Europe, and it will be presented at the European Congress of Radiology (ECR), March 4-8 in Vienna, Austria.

The re-engineered device includes advanced touchscreen technology that enables technologists to customize the contrast injection experience right at the patient’s side with new enhancements, including real-time variable flow rates, saline advance and saline jump.

The saline advance function tests a patient’s patency and vein integrity while the saline jump feature minimizes the amount of contrast a patient receives. The injector’s patented extravasation detection accessory (EDA) provides additional safety and peace of mind for the technologist. In addition, its eGFR calculator simplifies calculations for kidney evaluation function prior to contrast delivery. The risk of air embolisms to the patient is reduced due to the system’s built-in tilt sensor and lock.

For more information: www.braccoimaging.com


Additional Content

News | Contrast Media

Oct. 27, 2026 – Bracco has announced plans to invest $230 million to establish its first U.S. manufacturing facility for ...

Time October 28, 2026
arrow
News | Cardiac Imaging

Aug. 11, 2026 — Bracco Imaging recently announced that VueJect, its dedicated ultrasound contrast delivery system ...

Time August 12, 2026
arrow
News | Contrast Agents

June 15, 2026 – Bayer has announced that the U.S. Food and Drug Administration (FDA) approved Ambelvist (gadoquatrane) ...

Time June 16, 2026
arrow
News | FDA

May 18, 2026 — ACIST Medical Systems, a Bracco company, has received U.S. Food and Drug Administration (FDA) clearance ...

Time May 18, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...

Time March 04, 2026
arrow
Subscribe Now